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Summary
Background—The most common source of hematopoietic progenitor cells (HPCs) for
hematopoietic reconstitution comprises granulocyte colony-stimulating factor (G-CSF)-mobilized
peripheral blood stem cells (PBSCs). It has been proposed that endothelial progenitor cells (EPCs)
share precursors with HPCs, and that EPC release may accompany HPC mobilization to the
circulation following G-CSF administration.
Objective—To investigate EPC activity following HPC mobilization, and the direct effects of
exogenous G-CSF administration on human umbilical vein endothelial cells (HUVECs) and
endothelial outgrowth cells (EOCs), using in vitro and in vivo correlates of angiogenesis.
Patients/Methods—Heparinized venous blood samples were collected from healthy volunteers
and from cord blood at parturition. G-CSF-mobilized samples were collected before
administration, at apheresis harvest, and at follow-up. PBSCs were phenotyped by flow cytometry,
and cultured in standard colony-forming unit (CFU)-EPC and EOC assays. The effect of
exogenous G-CSF was investigated by addition of it to HUVECs and EOCs in standard tubule
formation and aortic ring assays, and in an in vivo sponge implantation model.
Results—Our data show that G-CSF mobilization of PBSCs produces a profound, reversible
depression of circulating CFU-EPCs. Furthermore, G-CSF administration did not mobilize
CD34+CD133− cells, which include precursors of EOCs. No EOCs were cultured from any
mobilized PBSCs studied. Exogenous G-CSF inhibited CFU-EPC generation, HUVEC and EOC
tubule formation, microvessel outgrowth, and implanted sponge vascularization in mice.
© 2010 International Society on Thrombosis and Haemostasis
Correspondence: Olga Tura, SNBTS Cell Therapy R&D Group, MRC Centre for Regenerative Medicine, The Chancellor’s Building,
University of Edinburgh, 49 Little France Crescent, EH16 4SU, UK. Tel.: +44 131 242 6259; fax: +44 131 242 6629.,
olga.tura@ed.ac.uk..
To cite this article: Tura O, Crawford J, Barclay GR, Samuel K, Hadoke PWF, Roddie H, Davies J, Turner ML. Granulocyte colony-
stimulating factor (G-CSF) depresses angiogenesis in vivo and in vitro: implications for sourcing cells for vascular regeneration
therapy. J Thromb Haemost 2010; 8: 1614–23.
Disclosure of Conflict of Interests
The authors state that they have no conflict of interest.
Europe PMC Funders Group
Author Manuscript
J Thromb Haemost. Author manuscript; available in PMC 2012 July 25.
Published in final edited form as:
J Thromb Haemost. 2010 July ; 8(7): 1614–1623. doi:10.1111/j.1538-7836.2010.03900.x.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Conclusions—G-CSF administration depresses both endothelial cell angiogenesis and
monocyte proangiogenic activity, and we suggest that any angiogenic benefit observed following
implantation of cells mobilized by G-CSF may come only from a paracrine effect from HPCs.
Keywords
angiogenesis; endothelial progenitor cells; granulocyte colony-stimulating factor; stem cell
therapy
Introduction
The recent discovery that endothelial progenitor cells (EPCs), which play a role in de novo
vascularization (vasculogenesis), circulate in adult blood and reside in the bone marrow
[1,2] prompted a range of studies based on localized implantation of autologous cells, aimed
at vascularizing ischemic tissue, particularly in myocardial and critical limb ischemias.
EPCs have not yet been definitively characterized, but have been linked with hematopoietic
progenitor cells (HPCs). EPCs and HPCs share a common ancestor, the hemangioblast, in
the developing fetus that may be retained in adult life [3]. HPCs derived from bone marrow
[bone marrow stem cells (BMSCs)] or peripheral blood (PB) [peripheral blood stem cells
(PBSCs)] following granulocyte colony-stimulating factor (G-CSF) administration have
been utilized as sources of EPCs for regenerative vascularization. A recent meta-analysis
showed that BMSC treatment generally improves short-term measurements of cardiac
function after myocardial infarction. However, there is, as yet, little evidence with which to
assess the long-term clinical effects of this treatment [4]. Although most studies so far
reported have used BMSCs for therapeutic angiogenesis, those in which G-CSF-mobilized
PBSCs were used gave comparable, mild improvements in cardiovascular lesions [5], and
both sources are generally regarded as adequate for therapeutic angiogenesis, just as they are
for hematopoiesis. To date, some studies have shown that EPCs, as well as HPCs, are
demonstrably mobilized by G-CSF [6-8]. However, this depends on how EPCs are defined
and interpreted: we can measure increases or decreases in EPC numbers following G-CSF
administration, depending on how EPCs are defined [9].
The current characterizations of EPCs have been based on phenotype and on colony assays.
HPCs are routinely defined for clinical use by their expression of CD34 or CD133 [10]. A
link between CD34/CD133 expression and the EPC phenotype was proposed almost from
the initial discovery of circulating EPCs [11,12], but recent studies have indicated that cells
expressing CD133 and their progeny remain hematopoietic, and only CD34+CD133− cells
are true EPCs [13,14]. True EPCs are defined as cells that, in culture over 3–4 weeks on
collagen, can give rise to endothelial outgrowth cells (EOCs) [14-16], whereas cells that
give rise over 5–6 days to colonies on fibronectin (colony-forming unit endothelial
progenitor cells) (CFU-EPCs), formerly proposed to be EPCs [17], are now recognized to be
generated by monocytes [16,18,19]. CFU-EPCs stain for many endothelial markers [20,21]
but also retain CD14 expression [22]. Monocytes can themselves mimic endothelial cells
(ECs) by upregulating expression of many markers held to be endothelial, and have
probably been mistaken for ECs in many investigations [22,23]. Although it is implicit in
many studies that the observed clinical benefit is delivered by EPCs, which are ultimately
incorporated as ECs into new vasculature, it is becoming apparent that neovascularization
can also be promoted indirectly by cells that release paracrine factors that promote
angiogenesis without being incorporated as ECs [24]. Although such cells may not be true
EPCs, their proangiogenic effect may be important, and this may be why so many different
cell phenotypes have been proposed to be EPCs [25,26].
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To date, G-CSF PBSC mobilization has been generally regarded as a practical and feasible
source of cells for therapeutic angiogenesis [27-29]. However, a recent meta-analysis
reported that G-CSF infusion alone had no significant clinical benefit in myocardial
infarction [30], and it was reported that G-CSF-mobilized PBSCs were less effective in
inducing ulcer healing than were BMSCs [31]. The mechanism by which G-CSF may
mobilize EPCs and/or enhance angiogenesis is still unknown. Similarly, the effects of G-
CSF on ECs and the vasculature have not been extensively studied [32]. In this study, we
have investigated circulating EPC activity following HPC mobilization by G-CSF
administration, and the direct effects of G-CSF on in vitro and in vivo correlates of
angiogenesis.
Materials and methods
Animals
Male C57B6J mice aged 10–12 weeks were purchased from Charles River Laboratories
(Tranent, UK) or Harlan Olac Ltd (Loughborough, UK). Experimental procedures were
approved by the University of Edinburgh ethics committee, and were authorized by the
Home Office under the Animals (Scientific Procedures) Act 1986.
Cell sources and sampling
Peripheral venous blood samples from healthy adults (normal PB) were collected into
heparin and from cord blood (CB) following elective caesarean section. For sequential
studies, healthy PBSC donors (mobilized PB donors) and PBSC transplant patients
(mobilized PB patients) donated 10 mL of venous PB before G-CSF mobilization (pre-G-
CSF); at apheresis harvest (post-G-CSF), and 1–2 months after harvest (follow-up). The G-
CSF protocol used in this work was the standard local clinical mobilization regimen. The G-
CSF (lenograstim) dose for healthy donors was 10 μg kg−1 d−1, given for four consecutive
days before collection of post-G-CSF cells (at apheresis) on day 5. Patient samples were
subjected to chemotherapy — salvage chemotherapy (lymphoma patients) or
cyclophosphamide (multiple myeloma patients) — followed by G-CSF (lenograstim),
starting at least 24 h following the last dose of chemotherapy — 5 μg kg−1 d−1 (lymphoma
patients) or 10 μg kg−1 d−1 (multiple myeloma patients) — and given for 6–7 days before
collection of post-G-CSF cells when CD34+ counts exceeded 10 × 106 L−1. Pre-G-CSF
treatment cells were collected 10–30 days prior to G-CSF administration. Healthy adult
donors (for allogeneic transplant) are the primary study subjects, and results for patients are
included for comparison. Further clinical, hematologic and laboratory data are reviewed
elsewhere (J. Crawford, MD thesis, University of Edinburgh, submitted). Appropriate
ethical informed consent was obtained from subjects in all cases. Mononuclear cells (MNCs)
were isolated by buoyant density centrifugation over Ficoll-Paque Plus (GE Healthcare,
Uppsala, Sweden).
Isolation of short-term (2 h) plastic-adherent MNCs
MNCs (30 × 106) in 5 mL of IMDM (Invitrogen, Paisley, UK) containing 10% fetal bovine
serum (Sigma, Dorset, UK) were plated in 25-cm2 Corning tissue culture flasks (Fisher
Scientific, Loughborough, UK) and incubated at 37 °C. After 2 h, adherent cells were
detached using 1 mL of trypsin–EDTA in saline (Sigma). Harvested cells were resuspended
in IMDM and characterized by flow cytometry for use in further experiments.
Flow cytometry analysis and sorting
Cells were directly stained and analyzed on a FACS Calibur flow cytometer (Becton
Dickinson, Oxford, UK), using CELLQUEST PRO software for phenotypic expression of surface
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markers, and analyzed using FCS EXPRESS (DeNovo Software, Los Angeles, CA, USA), as
described previously [9]. Cells were sorted using a FACS Aria flow cytometer (Becton
Dickinson), using DIVA software. Sorted populations were recovered and characterized by
further analysis. The anti-human monoclonal antibodies used for flow cytometry included
anti-CD34–fluorescein isothiocyanate, anti-CD14–phycoerythrin, anti-CD45–PerCP
(Becton Dickinson), and anti-CD133–allophycocyanin (Myltenyi Biotec, Bisley, UK).
CFU-EPCs
This assay, based on the method of Hill et al. [17], was performed using a commercial kit
according to the manufacturer’s recommendations (Stem Cell Technologies, Grenoble,
France). As previously described [9,20,21], 5 × 106 unmodified MNCs were resuspended in
EndoCult Liquid Medium (Stem Cell Technologies) and plated on fibronectin-coated six-
well plates (Becton Dickinson) for 2 days. The non-adherent cells were recovered,
resuspended in fresh medium, and transferred to a fibronectin-coated 24-well plate (Becton
Dickinson) at 1 × 106 per well in the presence or absence of G-CSF (100 ng mL−1) for a
further 3 days; the colonies per well were then counted, and the EPC frequency was
calculated. The concentration of G-CSF used in this and other in vitro assays described
below was based on a previously determined optimal dose for CD34+ PBSC expansion/
differentiation to neutrophils [33].
Culture of EOCs
EOC culture was performed as described by Ingram et al. [34]. Briefly, 30 × 106 MNCs
from normal PB or 10 × 106 MNCs from CB were resuspended in endothelial growth
medium (EBM-2; Lonza, Slough, UK) and plated onto type 1 rat tail collagen-coated six-
well tissue culture plates (Becton Dickinson). The cells were incubated at 37 °C with 5%
CO2 for 3–4 weeks. The medium was changed every 2 days for 7 days, and then twice a
week until first passage. Colonies were counted when they became evident but before they
became confluent.
In vitro vascular tubule formation assay
Matrigel matrix (Becton Dickinson) solution was thawed overnight at 4 °C, and all
plasticware was precooled. Human umbilical vein endothelial cells (HUVECs) (Lonza) and
EOCs were resuspended at 1 × 105 mL−1 in EBM-2 in the presence or absence of G-CSF
(100 ng −1mL). Five hundred microliters of cells were added to duplicate wells precoated
with 250 μL of Matrigel that had been allowed to solidify for 1 h at 37 °C. Capillary
structures and EC networks were examined by phase contrast microscopy (× 40 lens), using
an inverted microscope (Nikon Eclipse TS100-F, Nikon Instruments, Kingston Upon
Thames, UK). Pictures were taken at 4 h and at 22 h. The EC network was quantified from
the image fields by scoring the number of cell–cell connections.
In vitro angiogenesis: aortic ring assay
C57Bl6 mice were killed by asphyxiation in CO2. The thoracic aorta was removed, washed
in serum-free MCDB 131 medium (Invitrogen), cleaned of periadventitial tissue, and
divided into 1-mm rings. Aortic rings were embedded in 200 μL of Matrigel (Becton
Dickinson) and incubated at 37 °C in serum-free MCDB 131, with heparin, ascorbic acid
and GA1000 (Cambrex Biosciences, Wokingham, UK) in the presence or absence of G-CSF
(100 ng mL−1). The medium was changed every 48 h. All assays were performed in
triplicate. The growth of new vessels was counted at day 4 and day 8 by light microscopy.
TURA et al. Page 4
J Thromb Haemost. Author manuscript; available in PMC 2012 July 25.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Subcutaneous sponge implantation assay for in vivo vascularization
Mice were anesthetized with halothane, and a sterilized sponge cylinder (0.5 cm diameter, 1
cm long) (Caligen Foam, Accrington, UK) was implanted subcutaneously on each flank.
Each animal had an intervention-impregnated sponge [growth-factor-reduced (GFR)-
Matrigel + G-CSF] on one side and a control, vehicle-impregnated sponge (GFR-Matrigel
alone) on the other side. Twenty days after implantation, mice were killed, and sponges were
excised. Sponges were fixed in 4% formalin and embedded in paraffin wax. Sections (5 μm)
were stained with hematoxylin–eosin for identification of blood vessels, as previously
described [35]. Vessel density within sponges was determined using the mean of triplicate
Chalkley counts on each of two sections per sponge [36].
Statistical analysis
Unless otherwise stated, continuous variables are reported as mean ± standard error of the
mean. Statistical analyses were performed with GRAPHPAD PRISM 4 (Graph Pad Software, La
Jolla, CA, USA), using two-tailed Student’s t-test, Mann–Whitney U-test or Wilcoxon
paired tests where appropriate. A P-value of < 0.05 was considered to indicate statistical
significance.
Results
The effects of in vivo administration of a PBSC-mobilizing G-CSF regimen on indicators of
angiogenesis
The induced depression of CFU-EPC capacity in PB MNCs following G-CSF
administration is profound but transient—When individual healthy subjects (PBSC
donors) were followed sequentially, G-CSF administration caused a profound decline in
CFU-EPC activity from normal levels, which recovered with time (Fig. 1A). The CFU-EPC
activity was virtually abolished after G-CSF administration as compared with the pre-G-CSF
sample (P < 0.001, paired t-test, n = 21). CFU-EPC activity returned to almost basal levels
in follow-up samples after 1–2 months following completion of G-CSF treatment (P < 0.01,
paired t-test, n = 13). Similar depression and recovery of CFU-EPC activity following G-
CSF mobilization of PBSCs (for autologous transplantation) was seen in a large series of
hematology patients (data not shown).
G-CSF-mobilized PB MNCs are unable to generate CFU-EPCs and these are
not recovered by monocyte enrichment—Confirming what we have previously
reported [9], CFU-EPCs were most prevalent in normal PB MNCs and were virtually absent
from G-CSF-mobilized PB MNCs, whether from patient or healthy donor sources (Fig. 1B).
We found that CFU-EPCs were slightly increased (e.g. from 21 to 25 per 106 MNCs, n = 6)
when normalPB MNCs were enriched for monocytes (to around 80% CD14+) by 2 h of
adherence on uncoated culture plates. Further enrichment of monocytes (to 98%) by CD14+
selection by FACS further increased CFU-EPCs (e.g. from 25 to 41 per 106 MNCs, n = 6)
and completely removed CFU-EPCs from the CD14-depleted adherent cells. CFU-EPCs
were not found in CD34-enriched (> 90%) or CD133-enriched (> 90%) MNCs from
different HPC-rich sources (Table 1).
In a larger series studied by plastic adherence enrichment alone, normalPB MNCs generated
a mean of 37 CFU-EPCs per 106 cells plated, CB MNCs generated fewer than five CFU-
EPCs per 106 cells plated, and G-CSF-mobilized PB MNCs were virtually unable to form
any CFU-EPCs (0.6 CFU-EPCs per 106 cells plated (Fig. 1C). Whereas enrichment of
CD14+ cells by plastic adherence increased the number of CFU-EPCs slightly in normal PB
MNCs and significally in CB MNCs, no CFU-EPCs were seen when CD14-enriched cells
from G-CSF-mobilized MNCs were cultured.
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Mobilization of PB HPCs with G-CSF alters the phenotype proportions of
CD34+ cell subpopulations—G-CSF-mobilized PB samples had a more than 10-fold
higher proportion of CD34+ cells than normal PB samples (Fig. 2A). In agreement with our
earlier studies [9], G-CSF-mobilized PB samples had markedly higher coexpression of
CD133 by CD34+ cells (81.4% ± 10.5%) than normal PB samples (23.1% ± 18.2%). This
was true for both healthy donors (P < 0.001, Mann-Whitney U-test, n = 9) and for
autologous patients (Fig. 2B). Furthermore, in contrast to normal PB, in which a mean of
37% of CD34+ cells were CD45low, G-CSF-mobilized PB samples contained very low
proportions of CD34+CD45low cells (mean G-CSF-mobilized PB autologous, 1.64%; mean
G-CSF-mobilized PB allogeneic, 1.63%) (P < 0.001, Mann-Whitney U-test, n = 9) (Fig.
2C), and their absolute numbers were little increased in G-CSF-mobilized PB as compared
with normal PB, in contrast to total CD34+ numbers (Fig. 2D).
G-CSF-mobilized PB MNCs are unable to generate EOCs—CB MNCs (n = 15)
reliably generated EOC colonies when 10 × 106 MNCs were plated. For normal PB MNCs
(n = 12), at least 30 × 106 MNCs had to be plated. G-CSF-mobilized blood MNCs were
unable to form any EOC colonies for up to 30 × 106 MNCs plated (n = 7), either for healthy
donors or for patients (Table 2).
EOC potential is associated with CD34+CD133− cells—Enrichment of the CD34+
fraction of CB MNCs by magnetic bead cell sorting (> 90% purity) showed that this fraction
was the source of all EOC colonies. No colonies were found in CD34-depleted MNCs
(Table 2). Conversely, the CD133-enriched fraction from CB MNCs (> 90% purity) gave no
EOC colonies, and all of the EOC colonies were generated from the CD133-depleted
fraction. When the CD133− fraction was further sorted into CD34+ and CD34− fractions,
only the CD34+ (CD133−) fraction gave EOC colonies. The number of cells required to
produce EOC colonies fell dramatically with enrichment of CD34+CD133− cells.
Enrichment for the CD34+CD133− cell population increased the frequency of EOC
generation from CB MNCs, but not when G-CSF-mobilized blood MNCs were used.
The effect of direct addition of exogenous G-CSF on in vitro indicators of angiogenesis
The number of CFU-EPCs is reduced by addition of G-CSF to colony cultures
—The addition of G-CSF to normal PB MNCs in vitro significantly reduced the CFU-EPC
frequency as compared with controls without G-CSF (P < 0.01, paired t-test, n = 8) (Fig. 3).
The addition of 100 ng mL−1 vascular endothelial growth factor (VEGF) or stromal cell-
derived factor-1 (SDF-1) to the wells to which G-CSF had been added did not rescue colony
formation (data not shown).
Tubule formation by HUVECs and EOCs is reduced by G-CSF—Vascular tubule
formation by HUVECs in Matrigel showed a significant reduction at 22 h in the presence of
G-CSF as compared with controls (P < 0.01, paired t-test, n = 5) (Fig. 4C); a paired example
is shown in Fig. 4A,B. The addition of 100 ng mL−1 VEGF or SDF-1 to the wells with G-
CSF did not rescue tube formation (data not shown). EOCs grown on collagen behave like
HUVECs in many ways, and form tubules in Matrigel. As with HUVECs, tubule formation
by EOCs in Matrigel was inhibited by G-CSF (n = 5) (Fig. 4D–F).
Angiogenesis from mouse aortic rings in vitro is reduced by G-CSF—The
numbers of vessels formed from murine aortic rings cultured in vitro and scored after 4 and
8 days were reduced in the presence of G-CSF as compared with controls at both time points
(P < 0.05, paired t-test, n = 4, means of triplicates). Results scored at 8 days are shown in
Fig. 5C. A paired example is shown in Fig. 5A,B.
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In vivo spontaneous angiogenesis in subcutaneous sponge implants in mice
is inhibited by G-CSF—Control vehicle-impregnated sponges (GFR-Matrigel only) and
G-CSF-impregnated sponges (G-CSF in GRF-Matrigel) excised after 20 days following
implantation both appeared red on gross inspection, with lace-like coverings of blood
vessels. They also both showed infiltration of organized matrix and an abundance of blood
vessels. On histologic examination, all sponges exhibited vascularization, but G-CSF-
impregnated sponges had significantly fewer blood vessels than controls when scored by
Chalkley counts (P < 0.001, Mann–Whitney U-test, n = 4) (Fig. 6). A group of mice (n = 4)
implanted with untreated sponges (no GFR-Matrigel vehicle) on both flanks exhibited a
similar level of vasculogenesis as that seen in vehicle-impregnated sponges (GFR-Matrigel),
demonstrating that GFR-Matrigel as vehicle has no intrinsic effect on vascularization (not
shown).
Discussion
It is well established that G-CSF administration successfully mobilizes progenitor cells to
PB, and these cells are able to reconstitute the hematopoietic system; therefore, it is thought
that G-CSF mobilization might also increase the number of circulating EPCs. In this study,
we used PBSCs from subjects receiving G-CSF for HPC mobilization, to examine the
possibility that EPCs are mobilized into the circulation concurrently. We were unable to
detect EPCs in G-CSF-mobilized PBSCs, using several of the published EPC phenotypes.
G-CSF administration for HPC mobilization not only failed to mobilize EPCs, but also
inhibited angiogenesis in vitro and in vivo.
Neither G-CSF-mobilized PB MNCs nor enriched monocytes are able to generate CFU-
EPCs
Initial observations showed that, following administration of G-CSF to healthy allogeneic
PBSC donors, there was a profound depression of CFU-EPC generation [9]. This reduction
in endothelial colony potential has been consistently shown by independent observers in our
group and in over 70 different samples studied. Longitudinal analysis of sequential PB
samples from healthy donors undergoing PBSC mobilization showed that CFU-EPC
numbers were severely reduced immediately after G-CSF administration, but returned to
almost pretreatment levels within 2 months (Fig. 1A). Similar results have been obtained in
hematologic malignancy patients undergoing PBSC mobilization for autologous
transplantation, and may indicate that preceding chemotherapy does not markedly affect
many putative laboratory measures of PBSC or endothelial function. Although CFU-EPCs
were originally proposed by Hill et al. [17] as a correlate of EPC frequency, it is now
established that they represent an expression of the activity of CD14+ monocytes [37],
which possibly constitute a key proangiogenic monocyte subpopulation, not related to any
HPC population. Monocyte enrichment by plastic adherence increased the frequency of
CFU-EPC generation from umbilical cord MNCs but did not increase the frequency of CFU-
EPC generation from G-CSF-mobilized blood MNCs (Fig. 1C), which, in contrast to CB
monocytes, appear to be unresponsive in this assay.
A recognized, strong, inverse correlation between CFU-EPC frequency and cardiovascular
risk has been reported extensively (reviewed in [20,21]). This accumulation of reports is not
trivial, and indicates that CFU-EPC measurement can assess some aspects of angiogenic
capacity. Thus, although CFU-EPC measurement seems not to be an indicator of EPC
frequency, as originally proposed, depressed CFU-EPC activity in G-CSF-mobilized
samples probably reflects reduced monocyte proangiogenic capacity.
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G-CSF-mobilized PB MNCs are unable to generate EOCs
There are a number of claims that G-CSF mobilizes EPCs [6-8], but these depend on how
EPCs are defined and interpreted. A very few studies are based on a reported increase in
CFU-EPC frequency [7], and nearly all are based on putative phenotype characterization of
EPCs. Although the proposed phenotypes for EPC have been dominated by variants based
on coexpression of CD34 and CD133, the definitive phenotype of an EPC remains elusive.
Recently, it has been reported that true circulating EPCs (EOCs) are CD34-positive but
CD133-negative and CD45-negative, whereas cells expressing CD133 and CD45 remain
hematopoietic and do not give rise to true ECs [13,14,38]. Previous observations showed
that the HPCs in G-CSF-mobilized blood are predominantly CD34+CD133+ [9,39], so by
phenotype alone there is no evidence of mobilization of EOCs (contained in the
CD34+CD133− subpopulation) by G-CSF (Fig. 2B), and nor is there evidence that CD34+
cells with low or negligible expression of the panleukocyte marker CD45 are selectively
mobilized by G-CSF (Fig. 2C). Indeed, no EOCs could be cultured from G-CSF-mobilized
blood MNCs (30 × 106) from either autologous patients or allogeneic donors, whereas, in
most cases, at least one EOC colony can be found in comparable normal PB MNCs, so there
is no evidence that EOCs are mobilized by G-CSF. As there is little or no selective
mobilization of CD34+CD133–CD45− cells by G-CSF, this may account for the failure to
find EOCs in these samples. Furthermore, enrichment for the proposed EOC precursor
population (CD34+CD133−) by magnetic beads increased the frequency of EOC generation
from umbilical cord MNCs, but not from G-CSF-mobilized blood MNCs. We have no
evidence to judge whether EOCs are prsent at low frequency/absent or inactive in G-CSF-
mobilized MNCs.
G-CSF has a direct inhibitory effect on angiogenesis
Although some of the effects of G-CSF on CFU-EPCs in vivo might result from alteration of
the balance of different cell types in the circulation and dilution of some MNC
subpopulations by others, it can be shown that G-CSF has a direct effect in vitro on CFU-
EPCs. In paired MNC samples, the addition of G-CSF resulted in a decrease in CFU-EPC
frequency (Fig. 3). Furthermore, the addition of known angiogenesis-promoting cytokines
such as VEGF or SDF-1 to the G-CSF-treated MNCs did not rescue colony formation.
Similarly, it can be shown that G-CSF depresses the expression in vitro of accepted
endothelial cell functions, such as the formation of cell–cell links in human EC (HUVEC
and EOC) tubule formation in Matrigel (Fig. 4) and in microvessel outgrowth from mouse
aortic rings (Fig. 5).
The direct effect of G-CSF on angiogenesis was ultimately confirmed with the use of an in
vivo mouse model of angiogenesis (subcutaneous sponge implantation). Localized G-CSF
substantially inhibited spontaneous vascularization of sponges in vivo (Fig. 6), in direct
contrast to what was seen in paired sponges lacking G-CSF in the same animals. Honold et
al. [8] showed that EPCs in G-CSF-mobilized samples were transiently dysfunctional, owing
to the cleavage of the chemokine receptor CXCR4, which is directly involved in stem cell
homing. Thus, the observed reduction of endogenous blood vessel formation in the G-CSF-
treated sponge may reflect a localized decline in the ability to recruit potential murine
angiogenic cells. Preliminary evidence from our current work suggests that G-CSF may
downregulate the expression of certain cell surface receptors and adherence molecules,
which may impair the ability of cells to function in certain environments; this could explain
the observed CFU-EPC depression and might be important in endothelial function and/or
angiogenesis. This is currently under investigation.
In agreement with our findings, a recent meta-analysis reported that G-CSF infusion alone
has no significant clinical benefit in myocardial infarction [30], and G-CSF-mobilized
TURA et al. Page 8
J Thromb Haemost. Author manuscript; available in PMC 2012 July 25.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
PBSCs were reported to be less effective in inducing ulcer healing than BMSCs [31].
However, a significant number of reports to date have shown that cellular therapies
employing G-CSF-mobilized cells have some clinical benefit [27-29]. Thus, although G-
CSF may not selectively mobilize true EPCs as defined by EOCs, and although it may
inhibit monocyte proangiogenic activity and EC angiogenic activity, G-CSF does induce an
increase in the number of circulating HPCs, which might home to ischemic lesions [27] and
could therefore provide a paracrine effect without any incorporation into new vessels. These
may be equivalent to the cells provided from bone marrow, and if that is the principal effect
required in some aspects of therapeutic vascularization, then mobilized PBSCs may be as
beneficial as BMSCs in clinical use.
In summary, this study has shown that there is a profound reduction in the number of CFU-
EPCs following G-CSF administration, which recovers with time. To the best of our
knowledge, we are the first to show that there is no evidence of circulating EOCs following
G-CSF administration for mobilization of HPCs. G-CSF-mobilized PBSC were
predominantly CD34+CD133+ cells, which are almost certainly hematopoietic cells. The
presence in vitro of exogenous G-CSF had a direct antiangiogenic effect that was not
abrogated by the addition of proangiogenic factors.
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Fig. 1.
Influence of administration of granulocyte colony-stimulating factor (G-CSF) for
hematopoietic progenitor cell (HPC) mobilization (Mob) on colony-forming unit endothelial
progenitor cells (CFU-EPCs) in peripheral blood (PB) mononuclear cells (MNCs). (A)
There was a fall in CFU-EPCs following G-CSF administration to healthy adult HPC donors
and a subsequent rise in CFU-EPCs at 1–2-month follow-up after mobilization. (B) CFU-
EPCs in normal PB MNCs and in HPC-rich MNC sources. (C) CFU-EPCs in MNCs (black)
and following monocyte (CD14) enrichment by plastic adherence (grey). A P-value of <
0.05 was considered to indicate statistical significance (*P < 0.05; **P < 0.01; ***P <
0.001). Pre, pre-G-CSF administration; Post, post-G-CSF administration.
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Fig. 2.
Influence of administration of granulocyte colony-stimulating factor (G-CSF) on
hematopoietic progenitor cell (HPC) mobilization on CD34+ cells and CD34+
subpopulations in peripheral blood (PB) leukocytes. (A) CD34+ cells as a proportion of total
leukocytes in normal PB and in G-CSF-mobilized PB from healthy donors and from
hematologic malignancy patients in remission (mPB). (B) The proportion of CD34+ cells
coexpressing CD133 in normal PB and in G-CSF-mobilized PB from healthy donors and
from hematologic malignancy patients in remission. (C) The proportion of CD34+ cells with
low to negligible CD45 expression in normal PB and in G-CSF-mobilized PB from healthy
donors and from hematologic malignancy patients in remission. (D) Absolute numbers of
circulating HPC subpopulations per liter of PB: all CD34+ cells; CD34+ cells coexpressing
CD133; and CD34+ cells low in CD45 expression. The results are calculated from research
laboratory determination of total leukocyte counts and proportional subpopulations,
expressed as mean ± standard deviation (SD). A P-value of < 0.05 was considered to
indicate statistical significance (*P < 0.05; **P < 0.01; ***P < 0.001). Mob, mobilized;
WBC, white blood cell.
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Fig. 3.
Influence of exogenous granulocyte colony-stimulating factor (G-CSF) in vitro on colony-
forming unit endothelial progenitor cells (CFU-EPCs). (A) Representative microscopy
images of CFU-EPC formation (i) by normal peripheral blood mononuclear cells (MNCs)
and (ii) in the presence of exogenous G-CSF (100 ng mL−1). There was a significant
reduction in MNC CFU-EPCs in the presence of G-CSF as compared with paired samples
without G-CSF. A P-value of < 0.05 was considered to indicate statistical significance (*P <
0.05; **P < 0.01; ***P < 0.001).
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Fig. 4.
Influence of exogenous granulocyte colony-stimulating factor (G-CSF) in vitro on tubule
formation. (A, B) Representative microscopy images of (A) normal tubule formation by
human umbilical vein endothelial cells (HUVECs) and (B) tubule formation by HUVECs in
a paired culture with exogenous G-CSF added. (C) There was a significant reduction in
HUVEC tubule connections in the presence of G-CSF as compared with paired samples
without G-CSF. (D, E) Representative microscopy images of (D) normal tubule formation
by endothelial outgrowth cells (EOCs) and (E) tubule formation by EOCs in a paired culture
with exogenous G-CSF added. (F) There was a significant reduction in EOC tubule
connections in the presence of G-CSF as compared to paired samples without G-CSF. A P-
value of < 0.05 was considered to indicate statistical significance (*P < 0.05; **P < 0.01;
***P < 0.001).
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Fig. 5.
Influence of exogenous granulocyte colony-stimulating factor (G-CSF) in vitro on
microvessel outgrowth from mouse aortic rings. Representative microscopy images of (A)
normal microvessel outgrowth from mouse aortic ring and (B) microvessel outgrowth from
a paired aortic ring sample from the same mouse in the presence of added exogenous G-
CSF. (C) There was a significant reduction in microvessel outgrowth from mouse aortic
rings in the presence of G-CSF as compared with paired samples without G-CSF.
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Fig. 6.
Inhibition of angiogenesis in vivo by granulocyte colony-stimulating factor (G-CSF). There
was a reduction of spontaneous vascularization of subcutaneously implanted sponges
containing G-CSF in growth-factor-reduced Matrigel as compared with contralateral
sponges in the same animal containing growth-factor-reduced Matrigel alone. A P-value of
< 0.05 was considered to indicate statistical significance (*P < 0.05; **P < 0.01; ***P <
0.001).
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Table 1
Effect of subpopulation enrichment/depletion on colony-forming unit endothelial progenitor cells (CFU-EPCs)
in mononuclear cell (MNC) populations
Source
Number of
CFU-EPCs
per 106
MNCs plated
Unfractioned MNCs* 21
2-h adherent cells (> 80% CD14+)* 25
2-h non-adherent cells* 2
CD14-enriched (> 98%)* 41
CD14-depleted* 0
CD34-enriched (> 90%)† 0
CD34-depleted† 3
CD133-enriched (> 90%)† 0
CD133-depleted† 8
CFU-EPCs are slightly increased when normal peripheral blood MNCs are enriched for monocytes (to about 80% CD14+) by 2 h of adherence on
uncoated culture plates. Further enrichment of monocytes (to 98%) by CD14+ selection by fluorescence-activated cell sorting further increased
CFU-EPCs and completely removed CFU-EPCs from the CD14-depleted plastic-adherent cells. CFU-EPCs were not found in CD34-enriched (>
90%) or CD133-enriched (> 90%) MNCs from different HPC-rich cell sources. Their depleted column eluates tend to show reduced CFU-EPC
activity as compared with the unfractioned starting MNCs, which may imply some loss of CFU-EPC activity by retention on columns by adhesion,
implying these cells are adherent.
*
Paired normal peripheral blood samples (n = 6).
†Unpaired HPC-rich samples (bone marrow, cord blood, mobilized blood).
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Table 2
Attainment of endothelial outgrowth cell (EOC) colonies from different mononuclear cell (MNC) sources and
subpopulations
Source (cord blood MNCs)
EOC
colonies
found
Number of MNCs
plated for one
EOC colony
Unfractioned MNCs Yes 3 ×106
CD133-enriched (> 90%) No (> 1.3 × 106)
CD133-depleted Yes 0.5 × 106
CD34-enriched (> 90%) Yes 1.7 × 106
CD34-depleted No (> 3 × 106)
CD34+CD133+ (> 90%) No (> 1.65 × 106)
CD34+CD133-depleted Yes 0.002 × 106
EOCs can be routinely cultured from cord blood MNCs plated at 5–10 × 106 per well on collagen. For normal adult peripheral blood MNCs, 30 ×
106 MNCs per well are required to give approximately one EOC colony. From cord blood MNCs separated by magnetic beads, CD34-enriched
cells form EOCs, but their CD34-depleted eluates do not. CD133-enriched cells do not form EOCs, but their CD133-depleted eluates do: if the
CD133-depleted cells are further fractionated according to CD34 expression, the CD34-enriched (CD34+CD133−) cells form EOCs but the CD34−
eluates do not.
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